Shares of Biogen BIIB decreased 0.7% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share decreased 45.08% over the past year to $4.58, which missed the estimate of $4.87.
Revenue of $2,852,600,000 decreased by 22.29% from the same period last year, which beat the estimate of $2,800,000,000.
Outlook
Biogen said it sees FY21 adjusted EPS of $17-$18.50 and sales of $10.45 billion-$10.75 billion.
How To Listen To The Conference Call
Date: Feb 03, 2021
Time: 08:00 AM
ET Webcast URL: https://event.webcasts.com/starthere.jsp?ei=1421476&tp_key=3db5323113
Price Action
Company's 52-week high was at $374.99
Company's 52-week low was at $223.25
Price action over last quarter: Up 3.36%
Company Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.